

Global Transthyretin Amyloidosis Drug Market Growth 2022-2028

<https://marketpublishers.com/r/G76EA8ED4D58EN.html>

Date: December 2022

Pages: 107

Price: US\$ 3,660.00 (Single User License)

ID: G76EA8ED4D58EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Transthyretin amyloidosis is a slowly progressive disease in which abnormal deposits of a protein called amyloid occur in the body's organs and tissues of the person. It is a progressive and fatal rare disease that can destroy nerve cells. It is often considered difficult to recognize and diagnose properly, and treatment is generally critical. However, the most common symptoms include heart failure, chronic diarrhea, weight loss, dry mouth, constipation, carpal tunnel syndrome, impaired kidney function, and floaters.

The global market for Transthyretin Amyloidosis Drug is estimated to increase from US\$ million in 2021 to reach US\$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Transthyretin Amyloidosis Drug market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Transthyretin Amyloidosis Drug market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Transthyretin Amyloidosis Drug market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Transthyretin Amyloidosis Drug market is expected at value of US\$ million in

2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Transthyretin Amyloidosis Drug players cover Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals and BELLUS Health Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage

This latest report provides a deep insight into the global Transthyretin Amyloidosis Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Transthyretin Amyloidosis Drug market, with both quantitative and qualitative data, to help readers understand how the Transthyretin Amyloidosis Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:

The study segments the Transthyretin Amyloidosis Drug market and forecasts the market size by Type (Tafamidis, Patisiran and Inotersen), by Application (Hereditary Transthyretin Amyloidosis and Wild Transthyretin Amyloidosis.), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type

Tafamidis

Patisiran

Inotersen

Other

Segmentation by application

Hereditary Transthyretin Amyloidosis

Wild Transthyretin Amyloidosis

Segmentation by region

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Major companies covered

Pfizer Inc

AstraZeneca

Prothena Corporation plc

Ionis Pharmaceuticals

BELLUS Health Inc

Anylam Pharmaceuticals, Inc

Eidos Therapeutics, Inc

SOM BIOTECH

Abbvie, Inc

Bausch Health Companies Inc

Bristol Myers Squibb Company

GSK Plc

Merck KGaA

Sanofi

Chapter Introduction

Chapter 1: Scope of Transthyretin Amyloidosis Drug, Research Methodology, etc.

Chapter 2: Executive Summary, global Transthyretin Amyloidosis Drug market size (sales and revenue) and CAGR, Transthyretin Amyloidosis Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.

Chapter 3: Transthyretin Amyloidosis Drug sales, revenue, average price, global market share, and industry ranking by company, 2017-2022

Chapter 4: Global Transthyretin Amyloidosis Drug sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.

Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.

Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace

Chapter 10: Manufacturing cost structure analysis

Chapter 11: Sales channel, distributors, and customers

Chapter 12: Global Transthyretin Amyloidosis Drug market size forecast by region, by country, by type, and application.

Chapter 13: Comprehensive company profiles of the leading players, including Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals, BELLUS Health Inc, Alnylam Pharmaceuticals, Inc, Eidos Therapeutics, Inc, SOM BIOTECH and Abbvie, Inc, etc.

Chapter 14: Research Findings and Conclusion

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Transthyretin Amyloidosis Drug Annual Sales 2017-2028
 - 2.1.2 World Current & Future Analysis for Transthyretin Amyloidosis Drug by Geographic Region, 2017, 2022 & 2028
 - 2.1.3 World Current & Future Analysis for Transthyretin Amyloidosis Drug by Country/Region, 2017, 2022 & 2028
- 2.2 Transthyretin Amyloidosis Drug Segment by Type
 - 2.2.1 Tafamidis
 - 2.2.2 Patisiran
 - 2.2.3 Inotersen
 - 2.2.4 Other
- 2.3 Transthyretin Amyloidosis Drug Sales by Type
 - 2.3.1 Global Transthyretin Amyloidosis Drug Sales Market Share by Type (2017-2022)
 - 2.3.2 Global Transthyretin Amyloidosis Drug Revenue and Market Share by Type (2017-2022)
 - 2.3.3 Global Transthyretin Amyloidosis Drug Sale Price by Type (2017-2022)
- 2.4 Transthyretin Amyloidosis Drug Segment by Application
 - 2.4.1 Hereditary Transthyretin Amyloidosis
 - 2.4.2 Wild Transthyretin Amyloidosis
- 2.5 Transthyretin Amyloidosis Drug Sales by Application
 - 2.5.1 Global Transthyretin Amyloidosis Drug Sale Market Share by Application (2017-2022)
 - 2.5.2 Global Transthyretin Amyloidosis Drug Revenue and Market Share by Application (2017-2022)
 - 2.5.3 Global Transthyretin Amyloidosis Drug Sale Price by Application (2017-2022)

3 GLOBAL TRANSTHYRETIN AMYLOIDOSIS DRUG BY COMPANY

3.1 Global Transthyretin Amyloidosis Drug Breakdown Data by Company

3.1.1 Global Transthyretin Amyloidosis Drug Annual Sales by Company (2020-2022)

3.1.2 Global Transthyretin Amyloidosis Drug Sales Market Share by Company (2020-2022)

3.2 Global Transthyretin Amyloidosis Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Transthyretin Amyloidosis Drug Revenue by Company (2020-2022)

3.2.2 Global Transthyretin Amyloidosis Drug Revenue Market Share by Company (2020-2022)

3.3 Global Transthyretin Amyloidosis Drug Sale Price by Company

3.4 Key Manufacturers Transthyretin Amyloidosis Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Transthyretin Amyloidosis Drug Product Location Distribution

3.4.2 Players Transthyretin Amyloidosis Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR TRANSTHYRETIN AMYLOIDOSIS DRUG BY GEOGRAPHIC REGION

4.1 World Historic Transthyretin Amyloidosis Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Transthyretin Amyloidosis Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Transthyretin Amyloidosis Drug Annual Revenue by Geographic Region

4.2 World Historic Transthyretin Amyloidosis Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Transthyretin Amyloidosis Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Transthyretin Amyloidosis Drug Annual Revenue by Country/Region

4.3 Americas Transthyretin Amyloidosis Drug Sales Growth

4.4 APAC Transthyretin Amyloidosis Drug Sales Growth

4.5 Europe Transthyretin Amyloidosis Drug Sales Growth

4.6 Middle East & Africa Transthyretin Amyloidosis Drug Sales Growth

5 AMERICAS

5.1 Americas Transthyretin Amyloidosis Drug Sales by Country

5.1.1 Americas Transthyretin Amyloidosis Drug Sales by Country (2017-2022)

5.1.2 Americas Transthyretin Amyloidosis Drug Revenue by Country (2017-2022)

5.2 Americas Transthyretin Amyloidosis Drug Sales by Type

5.3 Americas Transthyretin Amyloidosis Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Transthyretin Amyloidosis Drug Sales by Region

6.1.1 APAC Transthyretin Amyloidosis Drug Sales by Region (2017-2022)

6.1.2 APAC Transthyretin Amyloidosis Drug Revenue by Region (2017-2022)

6.2 APAC Transthyretin Amyloidosis Drug Sales by Type

6.3 APAC Transthyretin Amyloidosis Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Transthyretin Amyloidosis Drug by Country

7.1.1 Europe Transthyretin Amyloidosis Drug Sales by Country (2017-2022)

7.1.2 Europe Transthyretin Amyloidosis Drug Revenue by Country (2017-2022)

7.2 Europe Transthyretin Amyloidosis Drug Sales by Type

7.3 Europe Transthyretin Amyloidosis Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Transthyretin Amyloidosis Drug by Country

8.1.1 Middle East & Africa Transthyretin Amyloidosis Drug Sales by Country
(2017-2022)

8.1.2 Middle East & Africa Transthyretin Amyloidosis Drug Revenue by Country
(2017-2022)

8.2 Middle East & Africa Transthyretin Amyloidosis Drug Sales by Type

8.3 Middle East & Africa Transthyretin Amyloidosis Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Transthyretin Amyloidosis Drug

10.3 Manufacturing Process Analysis of Transthyretin Amyloidosis Drug

10.4 Industry Chain Structure of Transthyretin Amyloidosis Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Transthyretin Amyloidosis Drug Distributors

11.3 Transthyretin Amyloidosis Drug Customer

12 WORLD FORECAST REVIEW FOR TRANSTHYRETIN AMYLOIDOSIS DRUG BY

GEOGRAPHIC REGION

- 12.1 Global Transthyretin Amyloidosis Drug Market Size Forecast by Region
 - 12.1.1 Global Transthyretin Amyloidosis Drug Forecast by Region (2023-2028)
 - 12.1.2 Global Transthyretin Amyloidosis Drug Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Transthyretin Amyloidosis Drug Forecast by Type
- 12.7 Global Transthyretin Amyloidosis Drug Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Pfizer Inc
 - 13.1.1 Pfizer Inc Company Information
 - 13.1.2 Pfizer Inc Transthyretin Amyloidosis Drug Product Offered
 - 13.1.3 Pfizer Inc Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.1.4 Pfizer Inc Main Business Overview
 - 13.1.5 Pfizer Inc Latest Developments
- 13.2 AstraZeneca
 - 13.2.1 AstraZeneca Company Information
 - 13.2.2 AstraZeneca Transthyretin Amyloidosis Drug Product Offered
 - 13.2.3 AstraZeneca Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.2.4 AstraZeneca Main Business Overview
 - 13.2.5 AstraZeneca Latest Developments
- 13.3 Prothena Corporation plc
 - 13.3.1 Prothena Corporation plc Company Information
 - 13.3.2 Prothena Corporation plc Transthyretin Amyloidosis Drug Product Offered
 - 13.3.3 Prothena Corporation plc Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.3.4 Prothena Corporation plc Main Business Overview
 - 13.3.5 Prothena Corporation plc Latest Developments
- 13.4 Ionis Pharmaceuticals
 - 13.4.1 Ionis Pharmaceuticals Company Information
 - 13.4.2 Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Product Offered

13.4.3 Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Ionis Pharmaceuticals Main Business Overview

13.4.5 Ionis Pharmaceuticals Latest Developments

13.5 BELLUS Health Inc

13.5.1 BELLUS Health Inc Company Information

13.5.2 BELLUS Health Inc Transthyretin Amyloidosis Drug Product Offered

13.5.3 BELLUS Health Inc Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 BELLUS Health Inc Main Business Overview

13.5.5 BELLUS Health Inc Latest Developments

13.6 Alnylam Pharmaceuticals, Inc

13.6.1 Alnylam Pharmaceuticals, Inc Company Information

13.6.2 Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Product Offered

13.6.3 Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Alnylam Pharmaceuticals, Inc Main Business Overview

13.6.5 Alnylam Pharmaceuticals, Inc Latest Developments

13.7 Eidos Therapeutics, Inc

13.7.1 Eidos Therapeutics, Inc Company Information

13.7.2 Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Product Offered

13.7.3 Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Eidos Therapeutics, Inc Main Business Overview

13.7.5 Eidos Therapeutics, Inc Latest Developments

13.8 SOM BIOTECH

13.8.1 SOM BIOTECH Company Information

13.8.2 SOM BIOTECH Transthyretin Amyloidosis Drug Product Offered

13.8.3 SOM BIOTECH Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 SOM BIOTECH Main Business Overview

13.8.5 SOM BIOTECH Latest Developments

13.9 Abbvie, Inc

13.9.1 Abbvie, Inc Company Information

13.9.2 Abbvie, Inc Transthyretin Amyloidosis Drug Product Offered

13.9.3 Abbvie, Inc Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Abbvie, Inc Main Business Overview

13.9.5 Abbvie, Inc Latest Developments

13.10 Bausch Health Companies Inc

13.10.1 Bausch Health Companies Inc Company Information

13.10.2 Bausch Health Companies Inc Transthyretin Amyloidosis Drug Product Offered

13.10.3 Bausch Health Companies Inc Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Bausch Health Companies Inc Main Business Overview

13.10.5 Bausch Health Companies Inc Latest Developments

13.11 Bristol Myers Squibb Company

13.11.1 Bristol Myers Squibb Company Company Information

13.11.2 Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Product Offered

13.11.3 Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Bristol Myers Squibb Company Main Business Overview

13.11.5 Bristol Myers Squibb Company Latest Developments

13.12 GSK Plc

13.12.1 GSK Plc Company Information

13.12.2 GSK Plc Transthyretin Amyloidosis Drug Product Offered

13.12.3 GSK Plc Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 GSK Plc Main Business Overview

13.12.5 GSK Plc Latest Developments

13.13 Merck KGaA

13.13.1 Merck KGaA Company Information

13.13.2 Merck KGaA Transthyretin Amyloidosis Drug Product Offered

13.13.3 Merck KGaA Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Merck KGaA Main Business Overview

13.13.5 Merck KGaA Latest Developments

13.14 Sanofi

13.14.1 Sanofi Company Information

13.14.2 Sanofi Transthyretin Amyloidosis Drug Product Offered

13.14.3 Sanofi Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Sanofi Main Business Overview

13.14.5 Sanofi Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Transthyretin Amyloidosis Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. Transthyretin Amyloidosis Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Tafamidis

Table 4. Major Players of Patisiran

Table 5. Major Players of Inotersen

Table 6. Major Players of Other

Table 7. Global Transthyretin Amyloidosis Drug Sales by Type (2017-2022) & (K Units)

Table 8. Global Transthyretin Amyloidosis Drug Sales Market Share by Type (2017-2022)

Table 9. Global Transthyretin Amyloidosis Drug Revenue by Type (2017-2022) & (\$ million)

Table 10. Global Transthyretin Amyloidosis Drug Revenue Market Share by Type (2017-2022)

Table 11. Global Transthyretin Amyloidosis Drug Sale Price by Type (2017-2022) & (US\$/Unit)

Table 12. Global Transthyretin Amyloidosis Drug Sales by Application (2017-2022) & (K Units)

Table 13. Global Transthyretin Amyloidosis Drug Sales Market Share by Application (2017-2022)

Table 14. Global Transthyretin Amyloidosis Drug Revenue by Application (2017-2022)

Table 15. Global Transthyretin Amyloidosis Drug Revenue Market Share by Application (2017-2022)

Table 16. Global Transthyretin Amyloidosis Drug Sale Price by Application (2017-2022) & (US\$/Unit)

Table 17. Global Transthyretin Amyloidosis Drug Sales by Company (2020-2022) & (K Units)

Table 18. Global Transthyretin Amyloidosis Drug Sales Market Share by Company (2020-2022)

Table 19. Global Transthyretin Amyloidosis Drug Revenue by Company (2020-2022) (\$ Millions)

Table 20. Global Transthyretin Amyloidosis Drug Revenue Market Share by Company (2020-2022)

Table 21. Global Transthyretin Amyloidosis Drug Sale Price by Company (2020-2022) &

(US\$/Unit)

Table 22. Key Manufacturers Transthyretin Amyloidosis Drug Producing Area Distribution and Sales Area

Table 23. Players Transthyretin Amyloidosis Drug Products Offered

Table 24. Transthyretin Amyloidosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Transthyretin Amyloidosis Drug Sales by Geographic Region (2017-2022) & (K Units)

Table 28. Global Transthyretin Amyloidosis Drug Sales Market Share Geographic Region (2017-2022)

Table 29. Global Transthyretin Amyloidosis Drug Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 30. Global Transthyretin Amyloidosis Drug Revenue Market Share by Geographic Region (2017-2022)

Table 31. Global Transthyretin Amyloidosis Drug Sales by Country/Region (2017-2022) & (K Units)

Table 32. Global Transthyretin Amyloidosis Drug Sales Market Share by Country/Region (2017-2022)

Table 33. Global Transthyretin Amyloidosis Drug Revenue by Country/Region (2017-2022) & (\$ millions)

Table 34. Global Transthyretin Amyloidosis Drug Revenue Market Share by Country/Region (2017-2022)

Table 35. Americas Transthyretin Amyloidosis Drug Sales by Country (2017-2022) & (K Units)

Table 36. Americas Transthyretin Amyloidosis Drug Sales Market Share by Country (2017-2022)

Table 37. Americas Transthyretin Amyloidosis Drug Revenue by Country (2017-2022) & (\$ Millions)

Table 38. Americas Transthyretin Amyloidosis Drug Revenue Market Share by Country (2017-2022)

Table 39. Americas Transthyretin Amyloidosis Drug Sales by Type (2017-2022) & (K Units)

Table 40. Americas Transthyretin Amyloidosis Drug Sales Market Share by Type (2017-2022)

Table 41. Americas Transthyretin Amyloidosis Drug Sales by Application (2017-2022) & (K Units)

Table 42. Americas Transthyretin Amyloidosis Drug Sales Market Share by Application

(2017-2022)

Table 43. APAC Transthyretin Amyloidosis Drug Sales by Region (2017-2022) & (K Units)

Table 44. APAC Transthyretin Amyloidosis Drug Sales Market Share by Region (2017-2022)

Table 45. APAC Transthyretin Amyloidosis Drug Revenue by Region (2017-2022) & (\$ Millions)

Table 46. APAC Transthyretin Amyloidosis Drug Revenue Market Share by Region (2017-2022)

Table 47. APAC Transthyretin Amyloidosis Drug Sales by Type (2017-2022) & (K Units)

Table 48. APAC Transthyretin Amyloidosis Drug Sales Market Share by Type (2017-2022)

Table 49. APAC Transthyretin Amyloidosis Drug Sales by Application (2017-2022) & (K Units)

Table 50. APAC Transthyretin Amyloidosis Drug Sales Market Share by Application (2017-2022)

Table 51. Europe Transthyretin Amyloidosis Drug Sales by Country (2017-2022) & (K Units)

Table 52. Europe Transthyretin Amyloidosis Drug Sales Market Share by Country (2017-2022)

Table 53. Europe Transthyretin Amyloidosis Drug Revenue by Country (2017-2022) & (\$ Millions)

Table 54. Europe Transthyretin Amyloidosis Drug Revenue Market Share by Country (2017-2022)

Table 55. Europe Transthyretin Amyloidosis Drug Sales by Type (2017-2022) & (K Units)

Table 56. Europe Transthyretin Amyloidosis Drug Sales Market Share by Type (2017-2022)

Table 57. Europe Transthyretin Amyloidosis Drug Sales by Application (2017-2022) & (K Units)

Table 58. Europe Transthyretin Amyloidosis Drug Sales Market Share by Application (2017-2022)

Table 59. Middle East & Africa Transthyretin Amyloidosis Drug Sales by Country (2017-2022) & (K Units)

Table 60. Middle East & Africa Transthyretin Amyloidosis Drug Sales Market Share by Country (2017-2022)

Table 61. Middle East & Africa Transthyretin Amyloidosis Drug Revenue by Country (2017-2022) & (\$ Millions)

Table 62. Middle East & Africa Transthyretin Amyloidosis Drug Revenue Market Share

by Country (2017-2022)

Table 63. Middle East & Africa Transthyretin Amyloidosis Drug Sales by Type (2017-2022) & (K Units)

Table 64. Middle East & Africa Transthyretin Amyloidosis Drug Sales Market Share by Type (2017-2022)

Table 65. Middle East & Africa Transthyretin Amyloidosis Drug Sales by Application (2017-2022) & (K Units)

Table 66. Middle East & Africa Transthyretin Amyloidosis Drug Sales Market Share by Application (2017-2022)

Table 67. Key Market Drivers & Growth Opportunities of Transthyretin Amyloidosis Drug

Table 68. Key Market Challenges & Risks of Transthyretin Amyloidosis Drug

Table 69. Key Industry Trends of Transthyretin Amyloidosis Drug

Table 70. Transthyretin Amyloidosis Drug Raw Material

Table 71. Key Suppliers of Raw Materials

Table 72. Transthyretin Amyloidosis Drug Distributors List

Table 73. Transthyretin Amyloidosis Drug Customer List

Table 74. Global Transthyretin Amyloidosis Drug Sales Forecast by Region (2023-2028) & (K Units)

Table 75. Global Transthyretin Amyloidosis Drug Sales Market Forecast by Region

Table 76. Global Transthyretin Amyloidosis Drug Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 77. Global Transthyretin Amyloidosis Drug Revenue Market Share Forecast by Region (2023-2028)

Table 78. Americas Transthyretin Amyloidosis Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 79. Americas Transthyretin Amyloidosis Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 80. APAC Transthyretin Amyloidosis Drug Sales Forecast by Region (2023-2028) & (K Units)

Table 81. APAC Transthyretin Amyloidosis Drug Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 82. Europe Transthyretin Amyloidosis Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 83. Europe Transthyretin Amyloidosis Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 84. Middle East & Africa Transthyretin Amyloidosis Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 85. Middle East & Africa Transthyretin Amyloidosis Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 86. Global Transthyretin Amyloidosis Drug Sales Forecast by Type (2023-2028) & (K Units)

Table 87. Global Transthyretin Amyloidosis Drug Sales Market Share Forecast by Type (2023-2028)

Table 88. Global Transthyretin Amyloidosis Drug Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 89. Global Transthyretin Amyloidosis Drug Revenue Market Share Forecast by Type (2023-2028)

Table 90. Global Transthyretin Amyloidosis Drug Sales Forecast by Application (2023-2028) & (K Units)

Table 91. Global Transthyretin Amyloidosis Drug Sales Market Share Forecast by Application (2023-2028)

Table 92. Global Transthyretin Amyloidosis Drug Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 93. Global Transthyretin Amyloidosis Drug Revenue Market Share Forecast by Application (2023-2028)

Table 94. Pfizer Inc Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 95. Pfizer Inc Transthyretin Amyloidosis Drug Product Offered

Table 96. Pfizer Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 97. Pfizer Inc Main Business

Table 98. Pfizer Inc Latest Developments

Table 99. AstraZeneca Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 100. AstraZeneca Transthyretin Amyloidosis Drug Product Offered

Table 101. AstraZeneca Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 102. AstraZeneca Main Business

Table 103. AstraZeneca Latest Developments

Table 104. Prothena Corporation plc Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 105. Prothena Corporation plc Transthyretin Amyloidosis Drug Product Offered

Table 106. Prothena Corporation plc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 107. Prothena Corporation plc Main Business

Table 108. Prothena Corporation plc Latest Developments

Table 109. Ionis Pharmaceuticals Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 110. Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Product Offered

Table 111. Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 112. Ionis Pharmaceuticals Main Business

Table 113. Ionis Pharmaceuticals Latest Developments

Table 114. BELLUS Health Inc Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 115. BELLUS Health Inc Transthyretin Amyloidosis Drug Product Offered

Table 116. BELLUS Health Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 117. BELLUS Health Inc Main Business

Table 118. BELLUS Health Inc Latest Developments

Table 119. Alnylam Pharmaceuticals, Inc Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 120. Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Product Offered

Table 121. Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 122. Alnylam Pharmaceuticals, Inc Main Business

Table 123. Alnylam Pharmaceuticals, Inc Latest Developments

Table 124. Eidos Therapeutics, Inc Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 125. Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Product Offered

Table 126. Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 127. Eidos Therapeutics, Inc Main Business

Table 128. Eidos Therapeutics, Inc Latest Developments

Table 129. SOM BIOTECH Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 130. SOM BIOTECH Transthyretin Amyloidosis Drug Product Offered

Table 131. SOM BIOTECH Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 132. SOM BIOTECH Main Business

Table 133. SOM BIOTECH Latest Developments

Table 134. Abbvie, Inc Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 135. Abbvie, Inc Transthyretin Amyloidosis Drug Product Offered

Table 136. Abbvie, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 137. Abbvie, Inc Main Business

Table 138. Abbvie, Inc Latest Developments

Table 139. Bausch Health Companies Inc Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 140. Bausch Health Companies Inc Transthyretin Amyloidosis Drug Product Offered

Table 141. Bausch Health Companies Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 142. Bausch Health Companies Inc Main Business

Table 143. Bausch Health Companies Inc Latest Developments

Table 144. Bristol Myers Squibb Company Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 145. Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Product Offered

Table 146. Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 147. Bristol Myers Squibb Company Main Business

Table 148. Bristol Myers Squibb Company Latest Developments

Table 149. GSK Plc Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 150. GSK Plc Transthyretin Amyloidosis Drug Product Offered

Table 151. GSK Plc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 152. GSK Plc Main Business

Table 153. GSK Plc Latest Developments

Table 154. Merck KGaA Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 155. Merck KGaA Transthyretin Amyloidosis Drug Product Offered

Table 156. Merck KGaA Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 157. Merck KGaA Main Business

Table 158. Merck KGaA Latest Developments

Table 159. Sanofi Basic Information, Transthyretin Amyloidosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 160. Sanofi Transthyretin Amyloidosis Drug Product Offered

Table 161. Sanofi Transthyretin Amyloidosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 162. Sanofi Main Business

Table 163. Sanofi Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Transthyretin Amyloidosis Drug
- Figure 2. Transthyretin Amyloidosis Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Transthyretin Amyloidosis Drug Sales Growth Rate 2017-2028 (K Units)
- Figure 7. Global Transthyretin Amyloidosis Drug Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Transthyretin Amyloidosis Drug Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Tafamidis
- Figure 10. Product Picture of Patisiran
- Figure 11. Product Picture of Inotersen
- Figure 12. Product Picture of Other
- Figure 13. Global Transthyretin Amyloidosis Drug Sales Market Share by Type in 2021
- Figure 14. Global Transthyretin Amyloidosis Drug Revenue Market Share by Type (2017-2022)
- Figure 15. Transthyretin Amyloidosis Drug Consumed in Hereditary Transthyretin Amyloidosis
- Figure 16. Global Transthyretin Amyloidosis Drug Market: Hereditary Transthyretin Amyloidosis (2017-2022) & (K Units)
- Figure 17. Transthyretin Amyloidosis Drug Consumed in Wild Transthyretin Amyloidosis
- Figure 18. Global Transthyretin Amyloidosis Drug Market: Wild Transthyretin Amyloidosis (2017-2022) & (K Units)
- Figure 19. Global Transthyretin Amyloidosis Drug Sales Market Share by Application (2017-2022)
- Figure 20. Global Transthyretin Amyloidosis Drug Revenue Market Share by Application in 2021
- Figure 21. Transthyretin Amyloidosis Drug Revenue Market by Company in 2021 (\$ Million)
- Figure 22. Global Transthyretin Amyloidosis Drug Revenue Market Share by Company in 2021
- Figure 23. Global Transthyretin Amyloidosis Drug Sales Market Share by Geographic Region (2017-2022)
- Figure 24. Global Transthyretin Amyloidosis Drug Revenue Market Share by

Geographic Region in 2021

Figure 25. Global Transthyretin Amyloidosis Drug Sales Market Share by Region (2017-2022)

Figure 26. Global Transthyretin Amyloidosis Drug Revenue Market Share by Country/Region in 2021

Figure 27. Americas Transthyretin Amyloidosis Drug Sales 2017-2022 (K Units)

Figure 28. Americas Transthyretin Amyloidosis Drug Revenue 2017-2022 (\$ Millions)

Figure 29. APAC Transthyretin Amyloidosis Drug Sales 2017-2022 (K Units)

Figure 30. APAC Transthyretin Amyloidosis Drug Revenue 2017-2022 (\$ Millions)

Figure 31. Europe Transthyretin Amyloidosis Drug Sales 2017-2022 (K Units)

Figure 32. Europe Transthyretin Amyloidosis Drug Revenue 2017-2022 (\$ Millions)

Figure 33. Middle East & Africa Transthyretin Amyloidosis Drug Sales 2017-2022 (K Units)

Figure 34. Middle East & Africa Transthyretin Amyloidosis Drug Revenue 2017-2022 (\$ Millions)

Figure 35. Americas Transthyretin Amyloidosis Drug Sales Market Share by Country in 2021

Figure 36. Americas Transthyretin Amyloidosis Drug Revenue Market Share by Country in 2021

Figure 37. United States Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 38. Canada Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 39. Mexico Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 40. Brazil Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 41. APAC Transthyretin Amyloidosis Drug Sales Market Share by Region in 2021

Figure 42. APAC Transthyretin Amyloidosis Drug Revenue Market Share by Regions in 2021

Figure 43. China Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 44. Japan Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 45. South Korea Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 46. Southeast Asia Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 47. India Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 48. Australia Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 49. Europe Transthyretin Amyloidosis Drug Sales Market Share by Country in 2021

Figure 50. Europe Transthyretin Amyloidosis Drug Revenue Market Share by Country in 2021

Figure 51. Germany Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 52. France Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 53. UK Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 54. Italy Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 55. Russia Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 56. Middle East & Africa Transthyretin Amyloidosis Drug Sales Market Share by Country in 2021

Figure 57. Middle East & Africa Transthyretin Amyloidosis Drug Revenue Market Share by Country in 2021

Figure 58. Egypt Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 59. South Africa Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 60. Israel Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 61. Turkey Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 62. GCC Country Transthyretin Amyloidosis Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 63. Manufacturing Cost Structure Analysis of Transthyretin Amyloidosis Drug in 2021

Figure 64. Manufacturing Process Analysis of Transthyretin Amyloidosis Drug

Figure 65. Industry Chain Structure of Transthyretin Amyloidosis Drug

Figure 66. Channels of Distribution

Figure 67. Distributors Profiles

I would like to order

Product name: Global Transthyretin Amyloidosis Drug Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/G76EA8ED4D58EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G76EA8ED4D58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970